Home/Pipeline/LNZ101 (aceclidine/brimonidine)

LNZ101 (aceclidine/brimonidine)

Presbyopia

Phase 3Development likely deprioritized

Key Facts

Indication

Presbyopia

Phase

Phase 3

Status

Development likely deprioritized

Company

LENZ Therapeutics

About LENZ Therapeutics

LENZ Therapeutics is focused on developing and commercializing innovative ophthalmic therapies, with its lead program targeting the vast, underserved market of presbyopia. The company's key achievement is the FDA approval of VIZZ™, a proprietary aceclidine-based eye drop designed to restore near vision by creating a 'pinhole camera' effect through pupil constriction. Its strategy involves a direct U.S. commercial launch while pursuing international licensing partnerships to maximize global reach. LENZ aims to establish VIZZ™ as the standard of care in pharmaceutical presbyopia treatment.

View full company profile

Therapeutic Areas

Ophthalmology Refractive Disorders

Other Presbyopia Drugs

Drug	Company	Phase	Status
Presbyopia Treatment	Viatris (2)	NDA Submitted	Active
Presbyopia-Correcting ICL	STAAR Surgical	Research & Development	Active R&D
LB-01	Lento Bio	Discovery/IND-Enabling	Active
LB-02	Lento Bio	Discovery	Active
Presbyopia-Correcting Contact Lenses	Clerio Vision	Development	Active
Intra-corneal Implant	MAG Optics	Pre-clinical	Active
NVK029	Vyluma	Phase 2	Active
ArtiPlus	Ophtec	Clinical Trials	Active
BRIMOCHOL™ PF	Tenpoint Therapeutics	NDA Submitted	Active
Qlosi™	Orasis Pharmaceuticals	Approved	Active
TSH‑001	TSH Biopharm	Phase 1/2	Active
DE-128A	Santen Pharmaceutical	Phase 2	Active